Eli Lilly is building four new manufacturing sites, the drug company announced Wednesday, and though the $27 billion price tag is hefty, that’s not the notable piece of the announcement. Perhaps the more interesting part is that the sites are being located in the U.

Eli Lilly has announced plans to expand its domestic medicine production in the US by establishing four new pharmaceutical manufacturing sites. The move increases the company's total US capital expansion commitments to more than $50bn since 2020.

Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company develops new drugs. The move comes as companies work to build goodwill with President Donald Trump,

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than the last—the company’s spree has begged the question: What will they do | At a press conference in Washington,

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States: New sites in Research Triangle Park and Concord,

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

U.S. Secretary of Commerce Howard Lutnick said Lilly was doing "exactly what the President was hoping would happen."